Blood Test To Determine Efficacy Of Lung Cancer Drug

by Gopalan on  May 1, 2010 at 10:55 AM Cancer News   - G J E 4
Blood test of lung cancer patients can reveal whether in a given case erlotinib could work, according to new data presented at the 2nd European Lung Cancer Conference in Geneva, Switzerland.
 Blood Test To Determine Efficacy Of Lung Cancer Drug
Blood Test To Determine Efficacy Of Lung Cancer Drug

Erlotinib is one of a class of drugs that specifically inhibits an important cell-surface molecule known as the epidermal growth factor receptor (EGFR), which is highly expressed in some forms of cancer, including lung cancer. By blocking this receptor, drugs such as erlotinib aim to slow tumor growth and proliferation.

The blood test proposed will seek out specific cancer protein 'fingerprints' in the blood making it possible to identify those tumors which are more likely to shrink when treated with erlotinib.

Prof David Carbone from Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, and Canadian colleagues analyzed blood samples from the NCIC Clinical Trials Group (NCIC CTG) BR.21 study that had shown that erlotinib improved survival compared to placebo in patients with advanced non-small-cell lung cancer who had already tried one or two other drugs.

In the new study, the researchers analyzed blood samples that had been taken from some patients before they started treatment in the BR.21 study. They performed this analysis on patients who received the drug and on patients who received the placebo, looking for specific proteomic profiles already known to predict outcomes in patients treated with EGFR-blockers.

"The bottom line is that the proteomic test --comparing 'good' and 'poor' profiles-- was strongly prognostic in both erlotinib and placebo arms," said Prof Carbone. "Proteomics 'good' patients also had a significantly higher response rate than proteomics 'poor' patients (9.8% vs. 0.9%, p=0.002).

Prof Carbone notes that there are other methods available to analyze the EGFR pathway of lung cancers, including sequencing of the EGFR gene, or a technique known as fluorescence in-situ hybridization (FISH) to assess EGFR gene copy number, in which tumor tissue samples are directly studied under a microscope.

"FISH overall was a better predictor of benefit, but can only be done with adequate biopsy tissue, which was available in this study only in 22% of patients. With the serum test, 99% of patients had a successful determination of proteomic status."

"Thus, I think this test may be of potential value in identifying a subgroup of patients with a good prognosis and who are likely to have response to erlotinib; it may be of particular value for those in whom tumor tissue is inadequate or unavailable," Prof Carbone said.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

View All